Gamma camera imaging in malignancy

European Journal of Cancer

Volumn 38, Issue 16, 2002, Pages 2157-2172

  Evans, J W ^a   Peters, A M ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORINE 18; GALLIUM 67; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; INDIUM 111; IODINE 123; IODINE 131; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; OCTREOTIDE; PERTECHNETIC ACID TC 99M; RADIOPHARMACEUTICAL AGENT; SELENIUM 53; SELENIUM DERIVATIVE; SUCCIMER TC 99M; TECHNETIUM 99M; TETROFOSMIN; THALLIUM 201; UNCLASSIFIED DRUG;

BONE CANCER; BRAIN TUMOR; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; GASTROINTESTINAL TUMOR; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; LYMPHOMA; MYELOMA; NEUROENDOCRINE TUMOR; NUCLEAR MEDICINE; ONCOLOGY; OVARY CANCER; PANCREAS TUMOR; PARANEOPLASTIC SYNDROME; PARATHYROID CARCINOMA; PERITONEUM TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SALIVARY GLAND TUMOR; SCINTILLATION CAMERA; SKIN CANCER; SOFT TISSUE CANCER; TESTIS CANCER; THYROID CANCER; THYROID MEDULLARY CARCINOMA; UTERINE CERVIX CANCER; UTERUS CANCER;

EID: 0036828158     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00412-4     Document Type: Article

References (72)

1. Delbeke D, Sandler MP, The role of hybrid camera in oncology. Semin Nucl Med 2000, 30, 268-280 [review].
2. Old S.E., Gilligan D., Balan K.K., Coulden R.A. Complete pathological response to chemotherapy for non-small cell lung cancer demonstrated by gamma camera positron emission tomography. Clin. Oncol. (R. Coll. Radiol.). 12:2000;53-55.
3. Glasspool RM, Evans TR. Clinical imaging of cancer metastasis. Eur J Cancer 2000, 36(13 Spec. No.), 1661-1670 [review].
4. D'Asseler Y, Vandenberghe S, Winter PD, et al. PET imaging using gamma cameras. Comput Med Imaging Graph 2001, 25, 87-96 [review].
5. Thrall J.H., Ziessman H.A. The Requisites of Nuclear Medicine St Louis, MI Mosby inc, 2001.
6. Pneumaticos S.G., Chatziioannou S.N., Moore W.H., Johnson M. The role of radionuclides in primary musculoskeletal tumors beyond the 'bone scan'. Crit. Rev. Oncol. Hematol. 37:2001;217-226 [review].
7. Takamura Y., Miyoshi Y., Taguchi T., Noguchi S. Prediction of chemotherapeutic response by Technetium 99m - MIBI scintigraphy in breast carcinoma patients. Cancer. 92:2001;232-239.
8. Blankenberg FG, Tait JF, Strauss HW. Apoptotic cell death: its implications for imaging in the next millennium. Eur J Nucl Med 2000, 27, 359-367 [review].
9. Weber WA, Haubner R, Vabuliene E, Kuhnast B, Wester HJ, Schwaiger M. Tumor angiogenesis targeting using imaging agents. J Nucl Med 2001, 45, 179-182 [review].
10. Kumar V. Evaluation of stannous oxidation in the preparation of ultrahigh-purity 99m Tc(V)-DMSA. Nucl. Med. Commun. 22:2001;1261-1266.
11. Yen T.C., King K.L., Yang A.H., Liu R.S., Yeh S.H. Comparative radionuclide imaging of metastatic insular carcinoma of the thyroid. value of technetium-99m-(V)DMSA J. Nucl. Med. 37:1996;78-80.
12. Hirano T., Otake H., Shibasaki T., Tamura M., Endo K. Differentiating histologic malignancy of primary brain tumors. pentavalent technetium-99m-DMSA J. Nucl. Med. 38:1997;20-26.
13. Hirano T., Otake H., Yoshida I., Endo K. Primary lung cancer SPECT imaging with pentavalent technetium-99m-DMSA. J. Nucl. Med. 36:1995;202-207.
14. Ohta H., Endo K., Konishi J.et al. Scintigraphic evaluation of aggressive fibromatosis. J. Nucl. Med. 31:1990;1632-1634.
15. Kole A.C., Pruim J., Nieweg O.E.et al. PET with L-[1-carbon-11]-tyrosine to visualize tumors and measure protein synthesis rates. J. Nucl. Med. 38:1997;191-195.
16. Jager P.L., Plaat B.E., de Vries E.G.et al. Imaging of soft-tissue tumors using L-3-[iodine-123]iodo-alpha-methyl-tyrosine single photon emission computed tomography. comparison with proliferative and mitotic activity, cellularity, and vascularity Clin. Cancer Res. 6:2000;2252-2259.
17. Harrington K.J., Mohammadtaghi S., Uster P.S.et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res. 7:2000;243-254.
18. O'Byrne KJ, Schally AV, Thomas A, Carney DN, Steward WP. Somatostatin, its receptors and analogs, in lung cancer. Chemotherapy 2001, 47(Suppl. 2), 78-108 [review].
19. Oberg K. Established clinical use of octreotide and lanreotide in oncology. Chemotherapy 2000, 47(Suppl. 2), 40-53 [review].
20. Behr TM, Gotthardt M. Barth A, Behe M. Imaging tumors with peptide-based radioligands. Q J Nucl Med 2001, 45, 189-200 [review].
21. Blum J., Handmaker H., Lister-James J., Rinne N. A multicenter trial with a somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules. Chest. 117:2000;1232-1238.
22. Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000, 7, 971-994 [review].
23. Nocaudie-Calzada M., Huglo D., Lambert M.et al. Efficacy of iodine-131 6beta-methyl-iodo-19-norcholesterol scintigraphy and computed tomography in patients with primary aldosteronism. Eur. J. Nucl. Med. 26:1999;1326-1332.
24. Shapiro B., Britton K.E., Hawkins L.A., Edwards C.R. Clinical experience with 75Se selenomethylcholesterol adrenal imaging. Clin. Endocrinol. (Oxf). 15:1981;19-27.
25. Verhaar-Langereis MJ, Zonnenberg, BA, de Klerk JM, Blijham GH. Radioimmunodiagnosis and therapy. Cancer Treat Rev. 2000, 26, 3-10 [review].
26. Bombardien E, Aliberti G, de Graaf C, Pauwels E, Crippa F. Positron emission tomography (PET) and other nuclear medicine modalities in staging gastrointestinal cancer. Semin Surg Oncol 2001, 20, 34-46 [review].
27. Kairemo K.J., Jekunen A.P., Bondestam S., Korppi-Tommola E.T., Savolainen S., Paavonen T. Detection of pseudomyxoma peritonei by radioimmunohistochemistry and radioimmunoscintigraphy. Cancer Biother. Radiopharm. 11:1996;325-334.
28. Xiang J., Moyana T., Matte G., Wilkinson A., Itzkowitz S., Oi Y. Establishment of a rat colonic carcinoma model for study of immunoreagents against the human tumor-associated TAG72 antigen. Cancer Biother. Radiopharm. 11:1996;335-344.
29. Amato R., Kim E.E., Prow D., Andreopoulos D., Kasi L.P. Radioimmunodetection of residual, recurrent or metastatic germ cell tumors using technetium-99 anti-(alpha-fetoprotein) Fab' fragment. J. Cancer Res. Clin. Oncol. 126:2000;161-167.
30. Dresel S., Kirsch C.M., Tatsch K., Zachoval R., Hahn K., Goldenberg D.M. Detection of hepatocellular carcinoma with a new alpha-fetoprotein antibody imaging kit. J. Clin. Oncol. 15:1997;2683-2690.
31. Fanelli M, Locopo N, Gattuso D, Gasparini G. Assessment of tumor vascularization: immunohistochemical and non-invasive methods. Int J Biol Markers 1999, 14, 218-231 [review].
32. Dewanjee M.K., Ghafouripour A.K., Kapadvanjwala M.et al. Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model. J. Nucl. Med. 35:1994;1054-1063.
33. Gauchez AS, Du Moulinet D'Hardemare A. Lunardi J, Vuillez JP, Fagret D. Potential use of radiolabeled antisense oligonucleotides in oncology. Anticancer Res 1999, 19, 4989-4997 [review].
34. Weissleder R, Mahmood U. Molecular imaging. Radiology 2001, 219, 316-333 [review].
35. Polan RL, Klein BD, Richman RH. Scintimammography in patients with minimal mammographic or clinical findings. Radiographics 2001, 21, 641-653 (discussion 653-655).
36. Wagner J.D., Schauwecker D.S., Davidson D., Wenck S., Jung S.H., Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J. Surg. Oncol. 77:2001;237-242.
37. Lim RB, Wong JH. Sentinel lymphadenectomy in gynecologic and solid malignancies other than melanoma and breast cancer. Surg Clin North Am 2000, 80, 1787-1998 [review].
38. Gervasoni JE Jr, Taneja C, Chung MA, Cady B. Biologic and clinical significance of lymphadenectomy. Surg Clin North Am 2000, 80, 1631-1673 [review].
39. Morita ET, Chang J, Leong SP. Principles and controversies in lymphoscintigraphy with emphasis on breast cancer. Surg Clin North Am 2000, 80, 1721-1739 [review].
40. Rosenman J. Incorporating functional imaging information into radiation treatment. Semin Radiat Oncol 2001, 11, 83-92 [review].
41. Front D., Bar-Shalom R., Mor M.et al. Aggressive non-Hodgkin lymphoma. early prediction of outcome with 67Ga scintigraphy Radiology. 214:2000;253-257.
42. Larson S.M. Molecular imaging in oncology. the diagnostic imaging "revolution" Clin. Cancer Res. 6:2000;2125.
43. Rosen L.S. Angiogenesis inhibition in solid tumors. Cancer J. 7 (Suppl. 3):2001;S120-S128.
44. Derlon J.M., Chapon F., Noel M.H.et al. Non-invasive grading of oligodendrogliomas. correlation between in vivo metabolic pattern and histopathology Eur. J. Nucl. Med. 27:2000;778-787.
45. Sasaki M., Kuwabara Y., Yoshida T.et al. A comparative study of thalclium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur. J. Nucl. Med. 25:1998;1261-1269.
46. Gudjonsson 0., Blomquist E., Lilja A., Ericson H., Bergstrom M., Nyberg G. Evaluation of the effect of high-energy proton irradiation treatment on meningiomas by means of 11C-L-methionine PET. Eur. J. Nucl. Med. 27:2000;1793-1799.
47. Derlon J.M., Chapon F., Noel M.H.et al. Non-invasive grading of oligodendrogliomas. correlation between in vivo metabolic pattern and histopathology Eur. J. Nucl. Med. 27:2000;778-787.
48. Nyberg G., Bergstrom M., Enblad P., Lilja A., Muhr C., Langstrom B. PET-methionine of skull base neuromas and meningiomas. Acta Otolaryngol. 117:1997;482-489.
49. Ferone D., Pivonello R., Lastoria S.et al. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics. correlation with somatostatin and dopamine D2 receptor scintigraphy Clin. Endocrinol. (Oxf). 54:2001;469-477.
50. Cohen M.S., Arslan N., Dehdashti F.et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose positron emission tomography. Surgery. 130:2001;941-946.
51. Udelsman R., Donovan P.I., Sokoll L.J. One hundred consecutive minimally invasive parathyroid explorations. Ann. Surg. 232:2000;331-339.
52. Ambrosoni P, Olaizola I, Heuguerot C, et al. The role of imaging techniques in the study of renal osteodystrophy. Am J Med Sci 2000, 320, 90-95 [review].
53. Gotway M.B., Reddy G.P., Webb W.R., Morita E.T., Clark O.H., Higgins C.B. Comparison between MR imaging and 99mTc MIBI scintigraphy in the evaluation of recurrent of persistent hyperparathyroidism. Radiology. 218:2001;783-790.
54. Neumann D.R., Esselstyn C.B. Jr., MacIntyre W.J., Chen E.Q., Go R.T., Licata A.A. Regional body FDG-PET in postoperative recurrent hyperparathyroidism. J. Comput. Assist. Tomogr. 21:1997;25-28.
55. Ugur O., Kostakglu L., Guler N.et al. Comparison of 99mTc(V)-DMSA, 201T1 and 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid. Eur. J. Nucl. Med. 23:1996;1367-1371.
56. Myers R.E., Johnston M., Pritchard K., Levine M., Oliver T. Baseline staging tests in primary breast cancer. a practice guideline CMAJ. 164:2001;1439-1444.
57. Kitagawa Y., Fujii H., Mukai M.et al. The role of the sentinel lymph node in gastrointestinal cancer. Surg. Clin. North Am. 80:2000;1799-1809.
58. Hoegerle S., Altehoefer C., Ghanem N.et al. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology. 220:2001;373-380.
59. Edgren M., Westlin J.E., Kalkner K.M., Sundin A., Nilsson S. [111In-DPTA-D-Phe1]-octreotide scintigraphy in the management of patients with advanced renal cell carcinoma. Cancer Biother. Radiopharm. 14:1999;59-64.
60. McCaffrey J.A., Reuter V.V., Herr H.W., Macapinlac H.A., Russo P., Motzer R.J. Carcinoid tumor of the kidney. The use of somatostatin receptor scintigraphy in diagnosis and management. Urol. Oncol. 5:2000;108-111.
61. Reinhardt M.J., Ehritt-Braun C., Vogelgesang D.et al. Metastatic lymph nodes in patients with cervical cancer. detection with MR imaging and EDG PET Radiology. 218:2001;776-782.
62. Rehm PK. Radionuclide evaluation of patients with lymphoma. Radiol Clin North Am 2001, 39, 957-978 [review].
63. Bar-Shalom R, Mor M, Yefremov N, Goldsmith SJ. The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment. Semin Nucl Med 2001, 31, 177-190 [review].
64. Rehm PK. Gallium-67 scintigraphy in the management: Hodgkin's disease and non-Hodgkin's lymphoma. Cancer Biother Radiopharm 1999, 14, 251-262 [review].
65. Gotway M.B., Reddy G.P., Webb W.R., Morita E.T., Clark O.H., Higgins C.B. Comparison between MR imaging and 99mTc MIBI scintigraphy in the evaluation of recurrent of persistent hyperparathyroidism. Radiology. 218:2001;783-790.
66. Kobayashi H., Kotoura Y., Hosono M.et al. Diagnostic value of Tc-99m (V) DMSA for chondrogenic tumors with positive Tc-99m HMDP uptake on bone scintigraphy. Clin. Nucl. Med. 20:1995;361-364.
67. Giannakenas C., Kalofonos H.P., Apostolopoulos D.et al. Scintigraphic imaging of sarcomatous tumors with [(111)In-DTPA-phe-l]octreotide. Oncology. 58:2000;18-24.
68. Aoki J., Watanabe H., Shinozaki T., Tokunaga M., Inoue T., Endo K. FDG-PET in differential diagnosis and grading of chondrosarcomas. J. Comput. Assist. Tomogr. 23:1999;603-608.
69. Jajic Z, Kovacic K, Jajic I, Jajic I. [Scintigraphy in the early diagnosis of the secondary hypertrophic osteoarthropathy syndrome]. Reumatizam 1997, 45, 1-4 [in Serbo-Croatian (Roman)].
70. Morgan B., Coakley F., Finlay D.B., Belton I. Hypertrophic osteoarthropathy in staging skeletal scintigraphy for lung cancer. Clin. Radiol. 51:1996;694-697.
71. Krause T., Eisenmann N., Reinhardt M.et al. Bone marrow scintigraphy using technetium-99m antigranulocyte antibody in malignant lymphomas. Ann. Oncol. 10:1999;79-85.
72. Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, 'Onko-PET III', 21 July and 19 September 2000. Eur J Nucl Med 2001, 28, 1707-1723 [review].